Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/176309 
Year of Publication: 
2014
Series/Report no.: 
Working Paper No. 291
Publisher: 
Indian Council for Research on International Economic Relations (ICRIER), New Delhi
Abstract: 
This paper attempts to evaluate the possible gains and losses arising from the gradual opening up of pharmaceutical trade between India and Pakistan. We explain the comparative advantages of both countries at a disaggregated level, followed by a qualitative analysis of various perceptions and experiences of Pakistan's pharmaceutical manufacturers with respect to trade with India. We find that a gradual opening up of pharmaceutical trade with India may allow Pakistan to enhance the quality of locally produced medicines through raw material, intermediate inputs, knowledge, and skills transfer from India. Pakistan, in the medium to long run, may also be able to diversify its pharmaceutical export base, reduce cost of production and achieve higher competitiveness through the development of value chain linkages with India. Such linkages are important to cater to the projected rise in demand for pharmaceuticals in Pakistan, Afghanistan and abroad.
Subjects: 
Trade
pharmaceutical
non-tariff barriers
India
Pakistan
JEL: 
F13
F14
F15
L11
L65
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.